C4 Ther­a­peu­tics gets $35M from Bet­ta Phar­ma­ceu­ti­cals to de­vel­op and mar­ket NSCLC drug in Chi­na

C4 Ther­a­peu­tics, one of the ear­ly play­ers in tar­get­ed pro­tein degra­da­tion, has linked up with Chi­na-based Bet­ta Phar­ma­ceu­ti­cals to de­vel­op C4’s non-small cell lung can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER